Journal article Open Access

Policy developments in regulatory approval

Temple, Robert

MARC21 XML Export

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="">
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="u"></subfield>
    <subfield code="a">Creative Commons Zero v1.0 Universal</subfield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2002-01-01</subfield>
  <controlfield tag="005">20200120171722.0</controlfield>
  <controlfield tag="001">1229361</controlfield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="p">openaire</subfield>
    <subfield code="o"></subfield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">Although radical changes in drug regulation are rare (e.g., the Federal Food, Drug and Cosmetic Act of 1938 and the 1962 amendment to the Act creating an effectiveness requirement), regulations and guidance do evolve significantly in the face of new problems and accumulating experience. Recent changes have been driven by the Food and Drug Administration Modernization Act (FDAMA), user fee legislation, the International Conference on Harmonization, recent safety related drug withdrawals, and concerns about trial ethics and investigator conflict of interest.

FDAMA and guidance developed in response to it has helped circumstances in which FDA would rely on a single study to support effectiveness and the circumstances in which surrogate endpoints could support approval. An ICH Document 'Choice of control group and related design issues in clinical trials' focussed attention on the ethics of placebo controls (acceptable, even if there is existing therapy, when the placebo‐treated patient will suffer no irreversible injury) and the design of 'equivalence' or 'non‐inferiority' trials.

There has been greatly increased attention to obtaining good dose‐response information and to assessing need for modifying treatment in demographic (age, gender, race) and concomitant disease (renal or hepatic function abnormalities) subgroups, and in assessing drug–drug interactions.

Other important trends are increasing reliance on non‐U.S. data, increasing numbers of FDA‐industry meetings during drug development, and new focus on risk assessment and risk management.</subfield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="s">64968</subfield>
    <subfield code="z">md5:b9963c2b2d86640cafdbec179708c8a8</subfield>
    <subfield code="u"></subfield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">article</subfield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Temple, Robert</subfield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="a">10.1002/sim.1298</subfield>
    <subfield code="2">doi</subfield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Policy developments in regulatory approval</subfield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="a">cc-by</subfield>
    <subfield code="2"></subfield>
Views 857
Downloads 261
Data volume 17.0 MB
Unique views 809
Unique downloads 253


Cite as